benzenesulfonic acid acetic acid-anhydride | 2183-55-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzenesulfonic acid acetic acid-anhydride
• 英文别名: Benzolsulfonsaeure-essigsaeure-anhydrid；Essigsaeure-benzolsulfonsaeure-anhydrid；Acetic benzenesulphonic anhydride；Acetylbenzolsulfonat；Phenylsulfonyl acetate；benzenesulfonyl acetate
• CAS: 2183-55-3
• 化学式: C₈H₈O₄S
• 分子量: 200.215
• InChiKey: BNZXJGMVVSASQT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  68.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  silver(I) acetate 、 苯磺酰氯 生成 benzenesulfonic acid acetic acid-anhydride
  参考文献：
  名称：

  Baroni, Atti della Accademia Nazionale dei Lincei, Classe di Scienze Fisiche, Matematiche e Naturali, Rendiconti, 1933, vol. <6>17, p. 1081,1084

  摘要：

  DOI：

文献信息

• Fused heterocyclic compounds
  申请人：Johnson A. James

  公开号：US20050250783A1

  公开（公告）日：2005-11-10

  A compound of formula I wherein m, n, A, B, D, E, G, H, Y, R 1 , R 2 , R 3 , R 4 , R 5 , and R 8 , are described herein.

  其中m、n、A、B、D、E、G、H、Y、R1、R2、R3、R4、R5和R8在本发明中有所描述。
• (E)-4-carboxystyrl-4-chlorobenzyl sulfone and pharmaceutical compositions thereof
  申请人：——

  公开号：US20030149109A1

  公开（公告）日：2003-08-07

  Pre-treatment with &agr;,&bgr; unsaturated aryl sulfones protects normal cells from the cytotoxic side effects of two classes of anticancer chemotherapeutics. Administration of a cytoprotective sulfone compound to a patient prior to anticancer chemotherapy with a mitotic phase cell cycle inhibitor or topoisomerase inhibitor reduces or eliminates the cytotoxic side effects of the anticancer agent on normal cells. The cytoprotective effect of the &agr;,&bgr; unsaturated aryl sulfone allows the clinician to safely increasing the dosage of the anticancer chemotherapeutic.

  使用α,β-不饱和芳基磺酮进行预处理可以保护正常细胞免受两类抗癌化疗药物的细胞毒副作用。在患者进行含细胞周期有丝分裂期抑制剂或拓扑异构酶抑制剂的抗癌化疗之前，给予一种细胞保护性磺酮化合物，可以减少或消除抗癌药物对正常细胞的细胞毒副作用。α,β-不饱和芳基磺酮的细胞保护作用使得临床医生可以安全地增加抗癌化疗药物的剂量。
• [EN] NOVEL PROCESS FOR THE PREPARATION OF CIS-NUCLEOSIDE DERIVATIVE<br/>[FR] NOVEAU PROCEDE DE PREPARATION DE DERIVE DE CIS-NUCLEOSIDE
  申请人：MATRIX LAB LTD

  公开号：WO2011095987A1

  公开（公告）日：2011-08-11

  The present invention relates to an improved process for the preparation of cis-nucleoside derivative of formula-1 involving chlorination of the compound of formula-2 followed by reaction with compound of formula-3 in presence of a base to get compound of formula-4, reacting the compound of formula-4 with an alkyl halide (RiX) to get a quaternary ammonium salt then with cytosine derivative of formula-5 to provide the compound of formula-6, optionally de-protecting the compound of formula-6 to the compound of formula-7, reducing compound of formula-7 with metal catalyst in presence of a buffer solution, then adding an organic acid to get the compound of formula-8, and converting the compound of formula-8 to cis-nucleoside derivative of formula-1. The present invention further relates to novel cis-nucleoside derivative of formula-8. The present invention also relates to a pharmaceutical composition comprising cis-nucleoside derivative of formula-1 with excipients.

  本发明涉及一种改进的过程，用于制备式-1的顺式核苷衍生物，包括将式-2的化合物进行氯化，然后与式-3的化合物在碱的存在下发生反应得到式-4的化合物，将式-4的化合物与烷基卤化物（RiX）反应得到季铵盐，然后与式-5的胞嘧啶衍生物反应得到式-6的化合物，可选择性地去保护式-6的化合物得到式-7的化合物，用金属催化剂在缓冲溶液中还原式-7的化合物，然后加入有机酸得到式-8的化合物，并将式-8的化合物转化为式-1的顺式核苷衍生物。本发明还涉及新型式-8的顺式核苷衍生物。本发明还涉及一种包含式-1的顺式核苷衍生物与赋形剂的药物组合物。
• [EN] UV ABSORBING COMPOUNDS<br/>[FR] COMPOSÉS ABSORBANT LES UV
  申请人：FUJIFILM MFG EUROPE BV

  公开号：WO2009038463A1

  公开（公告）日：2009-03-26

  The invention relates to new, highly efficient UV - absorbing compounds, a process for their manufacturing and to uses of these UV - absorbing compounds. The UV - absorbing compounds are in particular UV - A - absorbing compounds according to Formula (VI) or (VII): R2CH2 - N(R17)-(CR12)m-N(R17)-CH2R2 (VI) N(R17)3-n[(CR12)m-N(R17)-CH2R2]n} (VII)

  这项发明涉及新型高效UV吸收化合物，其制造过程以及这些UV吸收化合物的用途。这些UV吸收化合物特别是根据化学式（VI）或（VII）的UV-A吸收化合物：R2CH2 - N(R17)-(CR12)m-N(R17)-CH2R2（VI）N(R17)3-n[(CR12)m-N(R17)-CH2R2]n}（VII）
• Amine derivative compounds
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20030078426A1

  公开（公告）日：2003-04-24

  An amine compound of the formula (I): 1 wherein R 1 represents an optionally substituted carbamoyl group, etc., R 2 represents a hydrogen atom, etc., R 3 represents a C 1 -C 10 alkyl group etc., W 1 , W 2 and W 3 are the same or different and each represent a single bond or a C 1 -C 8 alkylene group, X, Y and Q represent a sulfur atom, etc., Z represents a ═CH— group, etc., Ar represents a benzene ring, etc. and L represents a hydrogen atom, etc., or a pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc.

  化合物的结构式（I）如下：其中R1代表可选择取代的氨基甲酰基团，R2代表氢原子等，R3代表C1-C10烷基等，W1、W2和W3相同或不同，每个代表单键或C1-C8烷基链，X、Y和Q代表硫原子等，Z代表═CH—基团等，Ar代表苯环等，L代表氢原子等，或其药理学上可接受的盐。这些化合物在治疗和/或预防糖尿病、高脂血症、动脉硬化、癌症等疾病方面具有用处。